
Pasithea Therapeutics Corp. Share Price
KTTA
$0.85
+$0.04 (4.91%) Last updated on 02 Sep, 2025 | 23:44 ISTPasithea Therapeutics Corp. Stock Performance
Open $0.81 | Prev. Close $0.81 | Circuit Range N/A |
Day Range $0.81 - $0.85 | Year Range $0.67 - $7.50 | Volume 1,229 |
Average Traded $0.83 |
Pasithea Therapeutics Corp. Share Price Chart
$0.85
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp. Historical Data
Day | Open | Close | Change % |
---|---|---|---|
02-Sep-25 | $0.81 | $0.85 | +0.00% |
02-Sep-25 | $0.81 | $0.85 | +4.81% |
29-Aug-25 | $0.78 | $0.81 | -3.57% |
28-Aug-25 | $0.82 | $0.84 | +10.67% |
27-Aug-25 | $0.72 | $0.76 | +7.66% |
25-Aug-25 | $0.70 | $0.70 | -0.70% |
22-Aug-25 | $0.71 | $0.71 | +0.71% |